36
Participants
Start Date
December 18, 2021
Primary Completion Date
April 14, 2023
Study Completion Date
April 14, 2023
CBP501 (16)
16 mg/m2
CBP501 (25)
25 mg/m2
Cisplatin
60mg/m2
Nivolumab
240 mg
Medical Oncology Hematology Consultants, PA, Newark
Virginia Cancer Specialists, PC, Arrington
Oncology Hematology Care, Inc., Cincinnati
University of Michigan hospital, Ann Arbor
Minnesota oncology Hematology, P.A., Minneapolis
Illinois Cancer Specialists, Arlington Heights
Ochsner Clinic Foundation, Los Angeles
Texas Oncology- McKinney, McKinney
Mary Crowley Medical Research Center, Dallas
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology-Northeast Texas, Tyler
Baylor Scott & White Medical Center, Temple
Texas Oncology-San Antonio Northeast, San Antonio
Texas Oncology-McAllen South Second Street, McAllen
Texas Oncology-Austin Midtown, Austin
University of Colorado Cancer Center, Aurora
Arizona Oncology Associates, PC-HOPE, Tucson
James D Sanchez, Henderson
Northwest Medical Specialties, Tacoma
Northwest Cancer Specialists, P.C., Vancouver
CanBas Co. Ltd.
INDUSTRY